PortalPublikationenDeepening responses associated with improved progression-fre...

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

Standard

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. / Goldschmidt, Hartmut; Dimopoulos, Meletios A; Rajkumar, S Vincent; Weisel, Katja C; Moreau, Philippe; Chng, Wee-Joo; Mikala, Gábor; Cavo, Michele; Ramasamy, Karthik; Suryanarayan, Kaveri; Teng, Zhaoyang; Labotka, Richard; Mateos, Maria Victoria.

in: LEUKEMIA, Jahrgang 34, Nr. 11, 11.2020, S. 3019-3027.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Goldschmidt, H, Dimopoulos, MA, Rajkumar, SV, Weisel, KC, Moreau, P, Chng, W-J, Mikala, G, Cavo, M, Ramasamy, K, Suryanarayan, K, Teng, Z, Labotka, R & Mateos, MV 2020, 'Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma', LEUKEMIA, Jg. 34, Nr. 11, S. 3019-3027. https://doi.org/10.1038/s41375-020-0819-8

APA

Goldschmidt, H., Dimopoulos, M. A., Rajkumar, S. V., Weisel, K. C., Moreau, P., Chng, W-J., Mikala, G., Cavo, M., Ramasamy, K., Suryanarayan, K., Teng, Z., Labotka, R., & Mateos, M. V. (2020). Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. LEUKEMIA, 34(11), 3019-3027. https://doi.org/10.1038/s41375-020-0819-8

Vancouver

Goldschmidt H, Dimopoulos MA, Rajkumar SV, Weisel KC, Moreau P, Chng W-J et al. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. LEUKEMIA. 2020 Nov;34(11):3019-3027. https://doi.org/10.1038/s41375-020-0819-8

Bibtex

@article{b63c2431287f4159ba93cda6e72d296a,
title = "Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma",
abstract = "In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.",
author = "Hartmut Goldschmidt and Dimopoulos, {Meletios A} and Rajkumar, {S Vincent} and Weisel, {Katja C} and Philippe Moreau and Wee-Joo Chng and G{\'a}bor Mikala and Michele Cavo and Karthik Ramasamy and Kaveri Suryanarayan and Zhaoyang Teng and Richard Labotka and Mateos, {Maria Victoria}",
year = "2020",
month = nov,
doi = "10.1038/s41375-020-0819-8",
language = "English",
volume = "34",
pages = "3019--3027",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

AU - Goldschmidt, Hartmut

AU - Dimopoulos, Meletios A

AU - Rajkumar, S Vincent

AU - Weisel, Katja C

AU - Moreau, Philippe

AU - Chng, Wee-Joo

AU - Mikala, Gábor

AU - Cavo, Michele

AU - Ramasamy, Karthik

AU - Suryanarayan, Kaveri

AU - Teng, Zhaoyang

AU - Labotka, Richard

AU - Mateos, Maria Victoria

PY - 2020/11

Y1 - 2020/11

N2 - In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.

AB - In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.

U2 - 10.1038/s41375-020-0819-8

DO - 10.1038/s41375-020-0819-8

M3 - SCORING: Journal article

C2 - 32327729

VL - 34

SP - 3019

EP - 3027

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 11

ER -